Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Q2 2023 · 10-Q
Revenue$381.27M$381.27M−4.2% vs Q2 2022 Net Income$4.18M$4.18M−90.7% vs Q2 2022 EPS Diluted$0.05$0.05−90.7% vs Q2 2022 Operating Income$12,504,000−79.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$12,731,000−77.7% Margins · derivedOperating margin3.3%−11.8 pt vs Q2 2022
Net margin1.1%−10.2 pt vs Q2 2022
ended Jun 30, 2023 · filed Jul 27, 2023 · 27 d after period end